Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The Rare Kidney Diseases Market?

The market for uncommon kidney ailments has seen robust growth in recent years. Its size is forecasted to increase from $2.76 billion in 2024 to $3.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. Factors contributing to growth during the historic period include heightened disease recognition, the designation of orphan drugs, patient education and advocacy, and international research collaborations.

Expectations are high for the rare kidney diseases market to experience robust growth in the coming years. The market is poised to enlarge to “$4.41 billion by 2029”, exhibiting a 9.8% compound annual growth rate. The increase during the forecast timeline may be ascribed to the rise of gene therapies, amplified investment in research of rare diseases, enhancements in stakeholder collaboration, and global undertakings for rare maladies. Notable trends for the forecast phase encompass patient-focused approaches, evidence and analytics from the actual world, regulatory advances, remote healthcare and monitoring, and international health directives.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

What Core Drivers Are Expected To Influence The Rare Kidney Diseases Market?

The advancement of the rare kidney disease market is forecasted to be fueled by government policies and monetary assistance for kidney ailments. Such aid is a form of financial backing provided by the government to chosen groups presenting innovative solutions or projects that enhance and boost public services and the economy. In the area of kidney disorders, aid serves to augment disease monitoring and elevate the standard of living for patients suffering from various kidney conditions. This is achieved through a holistic public health policy that collaborates with other health organizations and national bodies. For example, in July 2022, The United States House Committee on Appropriations pledged a series of investments for improving kidney health. This included $8.5 million in funds for the CDC’s chronic kidney disease program, with the goal of encouraging awareness, diagnosis, and treatment of kidney disease regularly. The National Living Donor Assistance Center received an additional gift of $1 million for organ donation, thus resulting in a consistent $8 million investment in innovation and research. Hence, the growth of the rare kidney disease market is being spurred by government policies and monetary support for kidney disorders.

Which Segmentation Categories Are Highlighted In The Rare Kidney Diseases Market Analysis?

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type Of Molecule: Small Molecules, Biologics

3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management

2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics

3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents

4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies

5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies

6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

Which Market Trends Are Expected To Define The Future Of The Rare Kidney Diseases Market?

The emerging trend of product innovation is being rapidly adopted in the rare kidney disease market. Key market stakeholders are ambitiously focusing on the invention of novel products to solidify their market presence. In illustration, STADA Arzneimittel AG, a German firm specialising in generics, specialty pharma, and over-the-counter consumer healthcare products, launched Kinpeygo (budesonide) in September 2022. This is the first-ever medication approved in the European Union specifically for the treatment of a rare kidney disease known as immunoglobulin A nephropathy (IgAN). These budesonide capsules, designed for modified-release, are the EU’s first and sole approved intervention for primary IgAN, a seldom, advancing autoimmune renal disease representing a significant unmet need. 25%-30% of patients diagnosed with this disease eventually reach a critical condition necessitating either dialysis or renal transplantation.

Which Companies Hold A Competitive Edge In The 215 Market?

Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Rare Kidney Diseases Market?

North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model